We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.
- Authors
Petrucci, Maria Teresa; Finsinger, Paola; Chisini, Marta; Gentilini, Fabiana
- Abstract
The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality of life of patients, driven by both the tolerability and antimyeloma activity of bortezomib, we analyzed data that have been published concerning different strategies used to improve its tolerability as once weekly and/or subcutaneous administration.
- Subjects
BORTEZOMIB; MULTIPLE myeloma treatment; THALIDOMIDE; MULTIPLE myeloma; QUALITY of life; PATIENTS
- Publication
Patient Preference & Adherence, 2014, Vol 8, p939
- ISSN
1177-889X
- Publication type
Article
- DOI
10.2147/PPA.S38142